What question did this study set out to answer?

The aim is to evaluate the combined prognostic value of Ki67 and PSA immunostaining in metastatic hormone-sensitive prostate cancer.

April 3, 2026Archivio Italiano di Urologia e Andrologia0 citationsOpen Access

Prognostic value of Ki67 and PSA-immunostaining in de novo metastatic hormone-sensitive prostate cancer

AFAna Marta Ferreira RJRoberto Jarimba ARA. Cristina Rego

Key Points

The aim is to evaluate the combined prognostic value of Ki67 and PSA immunostaining in metastatic hormone-sensitive prostate cancer.
Conducted an assessment of Ki67 and PSA immunostaining levels in patients with de novo metastatic hormone-sensitive prostate cancer.
Identified and categorized patients into risk subgroups based on Ki67 and PSA-IHC results.
Analyzed outcomes related to varying risk stratifications.
Defined a high-risk subgroup characterized by low PSA immunostaining and high Ki67 levels.
Patients in the high-risk subgroup exhibited a markedly worse prognosis compared to others.
Findings indicate the need for prospective validation of these stratifications.

Abstract

Combined Ki67 and PSA-IHC assessment refines risk stratification in de novo mHSPC, identifying a high-risk PSA-IHC low/Ki67 high subgroup with markedly worse prognosis. These findings warrant prospective validation.

Perguntar à IA

Bookmark

View Full Paper